NCT05216224Phase 2Completed

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Study sponsor: Aclaris Therapeutics, Inc. · ACRS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-12-23Actual
Enrollment · participants95Actual
Source updated2026-01-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12.. After: Measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12.

Check registry source